HLA-A and cancer: IMC-F106C efficiently activated T cells toward melanoma (MEL624, MEWO, SKMEL5, and C32—Fig. 4a), NSCLC (NCI-H1755 and NCI-H1703—Fig. 4b), and ovarian (OV56 and COV318—Fig. 4c) cancer cells that express PRAME target (i.e. PRAME+/HLA-A*02:01+) in a dose-dependent manner (representative PBMC donor is shown; additional PBMC donor data can be found in Fig. S4).